ZymeQuest(R), Inc. and Cambrex Bio Science Baltimore, Inc. today announced the signing of a process development and bulk manufacturing agreement under which Cambrex will develop a scalable process to produce ZymeQuest’s proprietary blood group A conversion enzyme for pre-pivotal studies.
